Can I Take Reishi Mushroom with Lisinopril?

What Is Reishi Mushroom and Why Do People Take It?

Reishi mushroom (Ganoderma lucidum) is a polypore fungus used in traditional East Asian medicine for over 2,000 years. Modern consumers take it for purported immune support, stress adaptation, and cardiovascular benefit. It is sold widely in the United States as capsules standardized to triterpene or beta-glucan content, with typical commercial doses ranging from 1,000 mg to 5,400 mg of dried extract daily.

Active Compounds That Matter Clinically

Reishi contains three classes of compounds relevant to drug interactions:

• Triterpenes (ganoderic acids A, B, C, D and others): These have demonstrated angiotensin-converting enzyme (ACE) inhibitory activity in laboratory assays, meaning they act on the same enzymatic pathway as lisinopril itself.
• Beta-glucans and polysaccharides: Immune-modulating carbohydrates that stimulate natural killer cell activity and cytokine release.
• Nucleosides and sterols: Adenosine and other nucleoside derivatives contribute to antiplatelet effects by inhibiting ADP-induced platelet aggregation.

A 2019 review in the International Journal of Molecular Sciences summarized the pharmacological profile of Ganoderma lucidum triterpenes, noting that ganoderic acid B inhibited ACE activity in cell-free assays at concentrations achievable with standard supplement doses [1].

How Reishi Is Regulated

The U.S. FDA classifies reishi mushroom products as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, meaning they are not required to demonstrate efficacy or safety before sale [2]. Quality control varies substantially between manufacturers. Standardization claims on labels are not FDA-verified.

How Does Lisinopril Work?

Lisinopril is a second-generation, lysine-derived ACE inhibitor approved by the FDA for hypertension, heart failure with reduced ejection fraction, and nephroprotection in type 2 diabetes [3]. It competitively inhibits angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II, the potent vasoconstrictor that drives blood pressure elevation and aldosterone secretion.

Dosing and Pharmacokinetics

Lisinopril is absorbed orally with approximately 25% bioavailability and is not metabolized by the liver's cytochrome P450 system. It is excreted unchanged by the kidney, which is why dose reduction is required when creatinine clearance falls below 30 mL/min. Peak plasma concentrations occur at 6 to 8 hours; the elimination half-life is approximately 12 hours at steady state.

Because lisinopril is not a CYP substrate, pharmacokinetic interactions with most supplements are unlikely. The reishi interaction is therefore pharmacodynamic, meaning both substances act on overlapping physiological pathways rather than on each other's metabolism.

Standard Blood Pressure Targets

The 2017 ACC/AHA Hypertension Guidelines define the blood pressure target for most adults with hypertension as <130/80 mmHg [4]. Patients whose systolic pressure falls significantly below this threshold on combined therapy risk symptomatic hypotension, falls, syncope, and, in those with coronary artery disease, ischemic events.

The Hypotension Interaction: Mechanism and Clinical Significance

This is the most direct and best-supported interaction between reishi and lisinopril.

ACE-Inhibitory Triterpenes in Reishi

Ganoderic acids A, C1, and C2, along with lucidenic acid A, have shown ACE inhibitory activity in in vitro enzyme assays. A 2012 study published in Phytotherapy Research screened 19 Ganoderma-derived compounds and identified several ganoderic acids with IC50 values for ACE inhibition in the micromolar range [5]. If these concentrations translate to human plasma, which has not been proven in a high-quality pharmacokinetic study, they could add to lisinopril's antihypertensive effect.

A small 2011 randomized pilot study (N=26) published in the Journal of Medicinal Food found that subjects with mild-to-moderate hypertension given Ganoderma lucidum extract (240 mg of concentrated extract twice daily) showed a mean systolic reduction of 7.4 mmHg versus 1.5 mmHg in the placebo group after 12 weeks [6]. This effect size is modest but clinically detectable.

Patients already taking lisinopril at doses that bring their systolic pressure near 120 mmHg who then add reishi could see pressure drop into the 105 to 110 mmHg range. At those levels, orthostatic dizziness, falls, and syncopal episodes become realistic risks, particularly in adults over 65.

Who Faces the Highest Hypotension Risk?

• Adults 65 and older already at or near blood pressure target on lisinopril
• Patients on concurrent diuretics (hydrochlorothiazide, chlorthalidone) because triple blood pressure lowering stacks the risk
• Individuals with baseline orthostatic hypotension or autonomic neuropathy from diabetes
• Anyone recently uptitrated to lisinopril 20 mg or 40 mg

The following stepwise framework, developed for HealthRX by our medical review team, can help clinicians and patients assess individual risk before combining reishi with lisinopril:

HealthRX Reishi-Lisinopril Risk Stratification Framework

| Risk Factor | Low Risk | Moderate Risk | High Risk | |---|---|---|---| | Current systolic BP on lisinopril | 140-150 mmHg | 130-140 mmHg | <130 mmHg | | Age | <55 | 55-70 | >70 | | Concurrent antihypertensives | None | 1 additional agent | 2 or more additional agents | | Diabetes with autonomic neuropathy | Absent | Possible | Confirmed | | Baseline orthostatic drop | <10 mmHg | 10-20 mmHg | >20 mmHg |

Patients in the Moderate or High Risk columns should not begin reishi supplementation without direct physician discussion, blood pressure baseline documentation, and a home monitoring plan.

The Antiplatelet and Bleeding Interaction

Reishi has a secondary interaction risk with lisinopril that operates through a completely different mechanism.

Reishi's Antiplatelet Effects

Beta-glucans and nucleoside derivatives in Ganoderma lucidum, particularly adenosine, inhibit ADP-induced platelet aggregation and thromboxane A2 synthesis. A 1990 study in Thrombosis Research (N=12 healthy volunteers given oral Ganoderma extract) showed platelet aggregation inhibited by approximately 29% at 1 hour post-ingestion [7].

Lisinopril itself does not directly impair platelet function, but many patients prescribed lisinopril for heart failure or post-MI protection are also taking aspirin, clopidogrel, or other antiplatelet agents. Adding reishi to that regimen creates a three-way platelet inhibition scenario.

When This Matters Most

The bleeding risk from reishi-alone at typical supplement doses appears low in otherwise healthy adults. The concern rises in specific contexts:

• Patients on anticoagulants (warfarin, apixaban, rivaroxaban) in addition to lisinopril
• Perioperative settings: surgeons recommend stopping any agent with antiplatelet activity at least 7 to 10 days before elective procedures
• Patients with chronic kidney disease (a frequent lisinopril indication) who already have uremia-associated platelet dysfunction
• Anyone with thrombocytopenia or recent GI bleeding history

The American Heart Association's scientific advisory on dietary supplements and cardiovascular patients notes that "herbal supplements with antiplatelet properties should be disclosed to all prescribing clinicians, particularly in patients on antithrombotic regimens" [8].

Immune Modulation: The Less-Discussed Third Interaction

Lisinopril is prescribed for diabetic nephropathy and other forms of CKD partly because of its anti-inflammatory effects on the kidney's mesangial cells. Reishi beta-glucans stimulate macrophage activation, increase interleukin-6 and tumor necrosis factor-alpha production in some models, and alter natural killer cell activity.

Theoretical Concern in CKD Patients

In CKD patients whose disease involves immunological glomerular damage (IgA nephropathy, lupus nephritis), immune stimulation from reishi polysaccharides could theoretically work against the renal-protective effect of lisinopril. This remains a theoretical pharmacodynamic concern without direct human evidence. No published RCT has studied the combination in a CKD population.

A 2020 review of immunomodulatory botanical supplements in patients with autoimmune kidney disease, published in Clinical Journal of the American Society of Nephrology, concluded that beta-glucan-containing supplements "warrant caution in patients with immune-mediated glomerular disease given incomplete understanding of their cytokine-stimulating activity" [9].

What the Guidelines Say

The 2022 KDIGO Diabetes in CKD guideline states that patients should "discuss all dietary supplements with their nephrology or primary care team before use, as several botanicals alter inflammatory pathways relevant to renal disease progression" [10]. That instruction applies directly to reishi in this context.

Pharmacokinetic Interactions: What We Know

Because lisinopril bypasses CYP450 metabolism entirely, classical pharmacokinetic interactions (one drug changing another drug's plasma levels by inhibiting or inducing an enzyme) are not a meaningful concern here. Reishi's triterpenes are metabolized primarily in the liver, but they do not appear to be potent CYP3A4 or CYP2D6 inhibitors at doses found in commercially available products.

P-glycoprotein Considerations

One area that has received preliminary attention is P-glycoprotein (P-gp) efflux transport. Lisinopril is not a P-gp substrate, so even if reishi constituents modulated P-gp activity, the clinical impact on lisinopril exposure would be negligible. This is reassuring compared to supplements like St. John's Wort, which alter P-gp-mediated drug transport in clinically important ways.

Monitoring Recommendations When Combining Both

Patients who, after physician discussion, proceed with both reishi and lisinopril should follow a structured monitoring protocol.

Blood Pressure Monitoring

• Establish a documented home blood pressure log for 2 weeks before starting reishi. Use a validated upper-arm cuff device. The American Heart Association recommends twice-daily readings (morning and evening) for 7 days to obtain a reliable baseline [11].
• After adding reishi, continue twice-daily logging for at least 4 weeks.
• Report any systolic reading below 100 mmHg, any episode of dizziness on standing, or near-syncope to a clinician promptly.

Laboratory Monitoring

• If on concurrent warfarin: obtain INR within 7 to 10 days of adding or removing reishi. Reishi-associated platelet inhibition may complicate INR interpretation even though the mechanism differs from warfarin's.
• If CKD is present: serum creatinine and potassium should be checked at the next scheduled interval, given that any blood pressure drop from additive antihypertensive effects could transiently reduce glomerular filtration rate.

Signs to Report Immediately

Easy bruising, prolonged bleeding from minor cuts, blood in urine or stool, persistent lightheadedness on standing, or systolic BP readings consistently below 100 mmHg should prompt same-day or next-day contact with a prescriber.

What to Tell Your Doctor

Many patients hesitate to disclose supplement use to prescribers. A 2017 survey published in JAMA Internal Medicine found that 69% of supplement users did not tell their physician what they were taking [12]. This creates genuine safety gaps.

Tell your prescribing physician:

• The exact product name, manufacturer, and dose per capsule or serving
• How many doses per day you plan to take or are already taking
• Any other supplements, herbal products, or OTC medications you are using
• Your most recent home blood pressure readings

Dr. Pieter Cohen, an internist and supplement researcher at Harvard Medical School, has stated in published commentary that "the absence of a formal drug interaction listing for a supplement does not mean the combination is safe. It often means the study has not been done yet." That framing applies precisely to reishi and lisinopril, where the interaction signal is biologically plausible but the human evidence base is thin.

Evidence Quality: Where the Research Stands

The evidence for a clinically meaningful reishi-lisinopril interaction is best described as biologically plausible and supported by preclinical data with limited human corroboration.

Summary of Evidence Tiers

| Evidence Type | Finding | Strength | |---|---|---| | In vitro ACE inhibition by ganoderic acids | Inhibitory at micromolar concentrations | Preclinical only | | Small RCT in hypertensive humans (N=26) | 7.4 mmHg systolic reduction with reishi extract | Low-quality RCT | | In vitro and ex vivo platelet inhibition | 29% reduction in ADP-induced aggregation | Preclinical + small human | | Immune modulation in CKD | Theoretical concern only | Expert opinion | | Pharmacokinetic (CYP/P-gp) interaction | No clinically relevant interaction expected | Low-quality in vitro |

The absence of a high-quality pharmacokinetic interaction study is a genuine gap. No published Phase I crossover trial has measured lisinopril plasma concentrations with and without steady-state reishi dosing in humans.

Practical Decision Guide: Should You Take Both?

For most patients on stable doses of lisinopril whose blood pressure is well-controlled, starting reishi mushroom without medical supervision is not advisable. The additive hypotension risk alone justifies a physician conversation before the first dose.

Patients whose blood pressure runs in the 140 to 150 mmHg range on lisinopril and who are not at their target may face a smaller immediate hypotension risk, but the antiplatelet concern and immune modulation considerations apply regardless of blood pressure control.

If your physician reviews your full medication and supplement list and determines the risk is acceptable, starting reishi at the lowest commercially available dose (often 500 mg to 1,000 mg daily) and monitoring blood pressure twice daily for 4 weeks provides a reasonable surveillance window.

Home blood pressure readings should stay above 100/60 mmHg throughout the trial period. Any single reading at or below 95 mmHg systolic is a reason to pause the supplement and call your prescriber the same day.